Page 146 - Annual report 2021-22

Annual Report 2021-22 |

UNDERSTANDING INTER COMPARTMENTAL CROSSTALK BETWEEN INSULIN-SENSITIVE AND INSULIN-
GAP0233
RESISTANT OBESE AND NON-OBESE PHENOTYPES USING ADIPOSE TISSUE.

TO EVALUATE PROTECTIVE/THERAPEUTIC EFFECTS OF NATURAL BIOACTIVE COMPONENTS IN
GAP0236
AMELIORATION OF DIESEL EXHAUST INDUCED LUNG PHYSIOLOGY
129
GAP0237 UNDERSTANDING THE ROLE OF NON CODING RNAS (S) IN ONTOGENESIS
IDENTIFICATION AND FUNCTIONAL VALIDATION OF CANDIDATE MICRORNA BIOMARKERS IN
GAP0241
CORONARY ARTERY DISEASE: AN EXPLORATORY STUDY

TO CONDUCT A SITUATION ANALYSIS OF CHEMICAL CONTAMINANTS IN FOOD IN THE WHO SOUTH-
CLP0037
EAST ASIA REGION
OLP1152 CLINIC EYE for Rapid COVID Detection

DEVELOPMENT OF `GENODERM MATRIX`, AN ONLINE PHENOTYPE-GENOTYPE CHARACTERIZATION
OLP1160 TOOL, TO ENABLE A RAPID, SCALABLE AND COST EFFECTIVE DIAGNOSTIC APPROACH IN PATIENTS WITH
GENODERMATOSES

OLP1161 OUTREACH ACTIVITIES AT IGIB

DU6 IMMUNOLOGY AND INFECTIOUS DISEASE BIOLOGY

MODERN INNOVATIVE SOLUTIONS FOR ENVIRONMENTAL/ OCCUPATIONAL LUNG HEALTH
MLP0137
CHALLENGES USING CLINICAL AND PRE-CLINICAL STRATEGIES
MLP2004 AUGMENTING IMMUNOGENIC RESPONSE TO COVID19 WITH RECOMBINANT BCG (AIRCOVR-BCG)

MLP2012 INTERCEPTING HOST IMMUNOMETABOLISM WITH GRANULOMA ADAPTED TUBERCLE BACILLI

MLP2101 MRNA PLATFORMS FOR VACCINE AND BIOTHERAPEUTICS

MLP2105 CSIR MULTI-CENTRIC LONG TERM T CELL IMMUNE MONITORING FOR COVID-19 (POV-COV)

MLP2106 DELINEATING NOVEL MECHANISMS OF ENHANCING ANTIBIOTIC EFFICACY AGAINST TB

INVESTIGATION OF MECHANISMS OF EMERGING DRUG RESISTANCE IN TRICHOPHYTON SP., THE
GAP0149
MAJOR CAUSATIVE AGENTS OF FUNGAL SKIN INFECTIONS
TOWARDS DIFFERENTIAL DIAGNOSIS OF TUBERCULOSIS AT EXTRAPULMONARY SITES USING BLOOD
GAP0156
BASED GENE SIGNATURES
UNRAVELLING MOLECULAR DETERMINANTS OF CALCIUM HOMEOSTASIS OF MYCOBACTERIUM
GAP0164
TUBERCULOSIS AND THEIR ROLE IN PATHOGENESIS

GAP0180 MECHANISM OF TRIGLYCERIDE MEDIATED CONTROL OF INFLAMMATION IN TUBERCULOSIS INFECTION

LIPID REMODELLING BY PATATINS OF MYCOBACTERIUM TUBERCULOSIS AND ITS ROLE IN THE MOUSE
GAP0199
MODEL OF TUBERCULOSIS
GAP0205 MACROPHAGE LIPID MOBILIZATION IN TUBERCULOSIS INFECTION (CEFIPRA REFERENCE NO. 62T4- L)

LIPID DROPLET ASSOCIATED PROTEINS: FUNCTIONS BEYOND LIPID METABOLISM IN M.TUBERCULOSIS
GAP0207
INFECTED MACROPHAGES
GAP0213 SERTRALINE INTERVENTION FOR ENHANCING ANTI-TB THERAPEUTIC REGIMEN (SINERG)